GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunoclin Corp (GREY:IMCL) » Definitions » EV-to-EBITDA

Immunoclin (Immunoclin) EV-to-EBITDA : -2.06 (As of May. 25, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Immunoclin EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Immunoclin's enterprise value is $3.82 Mil. Immunoclin's EBITDA for the trailing twelve months (TTM) ended in Oct. 2014 was $-1.86 Mil. Therefore, Immunoclin's EV-to-EBITDA for today is -2.06.

The historical rank and industry rank for Immunoclin's EV-to-EBITDA or its related term are showing as below:

IMCL's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 9.67
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), Immunoclin's stock price is $0.159277. Immunoclin's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2014 was $-0.300. Therefore, Immunoclin's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Immunoclin EV-to-EBITDA Historical Data

The historical data trend for Immunoclin's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunoclin EV-to-EBITDA Chart

Immunoclin Annual Data
Trend Feb12 Jan13 Jan14
EV-to-EBITDA
- - -4.15

Immunoclin Quarterly Data
May11 Aug11 Nov11 Feb12 May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Apr14 Jul14 Oct14
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -7.62 -3.94 -5.96

Competitive Comparison of Immunoclin's EV-to-EBITDA

For the Biotechnology subindustry, Immunoclin's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunoclin's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunoclin's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Immunoclin's EV-to-EBITDA falls into.



Immunoclin EV-to-EBITDA Calculation

Immunoclin's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=3.820/-1.856
=-2.06

Immunoclin's current Enterprise Value is $3.82 Mil.
Immunoclin's EBITDA for the trailing twelve months (TTM) ended in Oct. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunoclin  (GREY:IMCL) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Immunoclin's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.159277/-0.300
=At Loss

Immunoclin's share price for today is $0.159277.
Immunoclin's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.300.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Immunoclin EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Immunoclin's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunoclin (Immunoclin) Business Description

Traded in Other Exchanges
N/A
Address
9107 Wilshire Boulevard, Suite 450, Beverly Hills, CA, USA, 90210
Immunoclin Corp is engaged in immunology research and development skill to serve the pharmaceutical, biotechnology and food industries, providing comprehensive, clinical and basic science research expertise at a commercial scale and quality.

Immunoclin (Immunoclin) Headlines

No Headlines